Vestmark Advisory Solutions Inc. Has $3.20 Million Holdings in Novo Nordisk A/S (NYSE:NVO)

Key Points

• Vestmark Advisory Solutions Inc. increased its holdings in Novo Nordisk A/S by 72.9%, owning 46,036 shares valued at approximately $3.2 million as of the latest quarter.
• Recent analyst ratings for Novo Nordisk have seen UBS downgrade the stock from "buy" to "neutral," while BNP Paribas upgraded it to "neutral" with a target price of $54.00.
• Novo Nordisk recently declared a semi-annual dividend of $0.4119 per share, with a dividend yield of 240.0% and a payout ratio of 45.05%.

Vestmark Advisory Solutions Inc. lifted its position in shares of Novo Nordisk A/S (NYSE:NVO - Free Report) by 72.9% in the 1st quarter, according to the company in its most recent Form 13F filing with the Securities & Exchange Commission. The firm owned 46,036 shares of the company's stock after buying an additional 19,413 shares during the quarter. Vestmark Advisory Solutions Inc.'s holdings in Novo Nordisk A/S were worth $3,197,000 at the end of the most recent reporting period.

Several other institutional investors and hedge funds have also bought and sold shares of NVO. North Star Investment Management Corp. lifted its stake in shares of Novo Nordisk A/S by 18.2% in the first quarter. North Star Investment Management Corp. now owns 20,742 shares of the company's stock valued at $1,440,000 after buying an additional 3,200 shares in the last quarter. Bank of New York Mellon Corp increased its stake in shares of Novo Nordisk A/S by 6.0% in the first quarter. Bank of New York Mellon Corp now owns 839,802 shares of the company's stock worth $58,316,000 after purchasing an additional 47,804 shares in the last quarter. Stanley Laman Group Ltd. purchased a new position in shares of Novo Nordisk A/S in the first quarter worth about $390,000. Dover Advisors LLC bought a new position in shares of Novo Nordisk A/S in the first quarter valued at approximately $505,000. Finally, GAMMA Investing LLC boosted its position in shares of Novo Nordisk A/S by 9.6% in the first quarter. GAMMA Investing LLC now owns 9,466 shares of the company's stock valued at $657,000 after acquiring an additional 827 shares during the period. 11.54% of the stock is owned by institutional investors.

Analysts Set New Price Targets

Several equities research analysts have issued reports on NVO shares. UBS Group lowered shares of Novo Nordisk A/S from a "buy" rating to a "neutral" rating in a research report on Tuesday, August 5th. BNP Paribas Exane raised shares of Novo Nordisk A/S from an "underperform" rating to a "neutral" rating and set a $54.00 target price on the stock in a research note on Wednesday. Barclays reaffirmed an "equal weight" rating on shares of Novo Nordisk A/S in a research note on Wednesday, July 30th. Dbs Bank downgraded shares of Novo Nordisk A/S to a "sell" rating in a research report on Friday, April 25th. Finally, HSBC cut shares of Novo Nordisk A/S from a "buy" rating to a "hold" rating and set a $57.00 target price on the stock. in a report on Thursday, July 31st. One equities research analyst has rated the stock with a sell rating, twelve have issued a hold rating and two have given a buy rating to the stock. Based on data from MarketBeat.com, Novo Nordisk A/S has a consensus rating of "Hold" and a consensus target price of $83.75.

Novo Nordisk A/S Stock Performance

Shares of Novo Nordisk A/S stock opened at $52.43 on Friday. The stock has a market cap of $234.10 billion, a price-to-earnings ratio of 14.40, a PEG ratio of 1.75 and a beta of 0.63. The firm's 50-day moving average is $64.96 and its 200 day moving average is $70.44. Novo Nordisk A/S has a 1 year low of $45.05 and a 1 year high of $139.74. The company has a debt-to-equity ratio of 0.52, a current ratio of 0.78 and a quick ratio of 0.56.

Novo Nordisk A/S (NYSE:NVO - Get Free Report) last posted its earnings results on Wednesday, August 6th. The company reported $0.97 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.93 by $0.04. The business had revenue of $11.69 billion for the quarter, compared to analysts' expectations of $77.51 billion. Novo Nordisk A/S had a net margin of 35.60% and a return on equity of 78.64%. Sell-side analysts anticipate that Novo Nordisk A/S will post 3.84 EPS for the current fiscal year.

Novo Nordisk A/S Cuts Dividend

The firm also recently declared a semi-annual dividend, which will be paid on Tuesday, August 26th. Stockholders of record on Monday, August 18th will be given a dividend of $0.4119 per share. The ex-dividend date of this dividend is Monday, August 18th. This represents a dividend yield of 240.0%. Novo Nordisk A/S's dividend payout ratio is presently 45.05%.

Novo Nordisk A/S Profile

Novo Nordisk A/S, together with its subsidiaries, engages in the research and development, manufacture, and distribution of pharmaceutical products in Europe, the Middle East, Africa, Mainland China, Hong Kong, Taiwan, North America, and internationally. It operates in two segments, Diabetes and Obesity Care, and Rare Disease.

Want to see what other hedge funds are holding NVO? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Novo Nordisk A/S (NYSE:NVO - Free Report).

This instant news alert was generated by narrative science technology and financial data from MarketBeat in order to provide readers with the fastest and most accurate reporting. This story was reviewed by MarketBeat's editorial team prior to publication. Please send any questions or comments about this story to contact@marketbeat.com.